On Tuesday, Akebia Therapeutics Inc (NASDAQ: AKBA) opened at On Tuesday, remained unchanged from the last session, before settling in for the closing price of $1.80. Price fluctuations for AKBA have ranged from $0.80 to $2.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -8.86%. Company’s average yearly earnings per share was noted -9.12% at the time writing. With a float of $209.50 million, this company’s outstanding shares have now reached $211.54 million.
Let’s determine the extent of company efficiency that accounts for 167 employees. In terms of profitability, gross margin is 63.13%, operating margin of -20.45%, and the pretax margin is -27.07%.
Akebia Therapeutics Inc (AKBA) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Akebia Therapeutics Inc is 3.98%, while institutional ownership is 28.71%. The most recent insider transaction that took place on Mar 03 ’25, was worth 84,928. In this transaction CEO and President of this company sold 46,409 shares at a rate of $1.83, taking the stock ownership to the 2,557,921 shares. Before that another transaction happened on Mar 03 ’25, when Company’s SVP, Chief Medical Officer sold 7,144 for $1.83, making the entire transaction worth $13,074. This insider now owns 809,090 shares in total.
Akebia Therapeutics Inc (AKBA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.12% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Check out the current performance indicators for Akebia Therapeutics Inc (AKBA). In the past quarter, the stock posted a quick ratio of 1.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.16 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Looking closely at Akebia Therapeutics Inc (NASDAQ: AKBA), its last 5-days average volume was 2.38 million, which is a jump from its year-to-date volume of 2.25 million. As of the previous 9 days, the stock’s Stochastic %D was 25.31%. Additionally, its Average True Range was 0.09.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 47.19%, which indicates a significant increase from 17.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.43% in the past 14 days, which was lower than the 58.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0042, while its 200-day Moving Average is $1.5653. However, in the short run, Akebia Therapeutics Inc’s stock first resistance to watch stands at $1.8533. Second resistance stands at $1.9067. The third major resistance level sits at $1.9733. If the price goes on to break the first support level at $1.7333, it is likely to go to the next support level at $1.6667. Should the price break the second support level, the third support level stands at $1.6133.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are currently 218,181K shares outstanding in the company with a market cap of 392.73 million. Presently, the company’s annual sales total 194,620 K according to its annual income of -51,930 K. Last quarter, the company’s sales amounted to 37,430 K and its income totaled -20,040 K.
